Patents Assigned to Erimos Pharmaceuticals, LLC
-
Patent number: 11844768Abstract: Nordihydroguaiaretic acid (NDGA) derivatives, including terameprocol (TMP) have utility as anti-viral agents for use on patients infected with or at risk of infection with a coronavirus, including SARS-CoV-2. In vitro studies show coronavirus-infected cells treated with 0.2 ?M-20 ?M TMP show reduced viral RNA activity in vitro. Treatment-related cytotoxicity is not shown at 0.2 ?M TMP with a low percentage of cytotoxicity shown at 5 ?M TMP. In application, the NDGA derivatives may be administered to a patient intravenously at a molar concentration of 0.1-50 ?M or orally at a molar concentration of 0.1-100 ?M.Type: GrantFiled: January 14, 2022Date of Patent: December 19, 2023Assignee: Erimos Pharmaceuticals, LLCInventors: Jeffrey Khoo, Stephan D. Glenn
-
Publication number: 20170044121Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.Type: ApplicationFiled: October 31, 2016Publication date: February 16, 2017Applicant: Erimos Pharmaceuticals LLCInventors: Jonathan Daniel Heller, Qingqi Chen, Rocio Alejandra Lopez, Amanda Jean Morris
-
Patent number: 9481660Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.Type: GrantFiled: April 7, 2014Date of Patent: November 1, 2016Assignee: ERimos Pharmaceuticals, LLCInventors: Jonathan Daniel Heller, Qingqi Chen, Rocio Alejandra Lopez, Amanda Jean Morris
-
Patent number: 9067875Abstract: Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.Type: GrantFiled: May 14, 2012Date of Patent: June 30, 2015Assignee: ERIMOS PHARMACEUTICALS LLCInventors: Qingqi Chen, Rocio Alejandra Lopez, Jonathan Daniel Heller, Amanda Jean Morris
-
Publication number: 20140221384Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.Type: ApplicationFiled: April 7, 2014Publication date: August 7, 2014Applicant: ERIMOS PHARMACEUTICALS LLCInventors: Jonathan Daniel Heller, Qingqi Chen, Rocio Alejandra Lopez, Amanda Jean Morris
-
Patent number: 8691845Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.Type: GrantFiled: July 30, 2012Date of Patent: April 8, 2014Assignee: Erimos Pharmaceuticals LLCInventors: Jonathan Daniel Heller, Qingqi Chen, Rocio Alejandra Lopez, Amanda Jean Morris
-
Patent number: 8440648Abstract: The present invention provides for compositions, kits and methods for treatment of intraepithelial neoplasia, where the compositions include catecholic butanes, which include NDGA derivatives.Type: GrantFiled: July 19, 2005Date of Patent: May 14, 2013Assignees: Erimos Pharmaceuticals LLC, University of Maryland, Baltimore, Johns Hopkins UniversityInventors: Neil Frazer, Jonathan Heller, Rocio Lopez, Melissa Rhodes, Ru Chih C. Huang, Richard Dalby, Niharika Khanna
-
Publication number: 20130053378Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.Type: ApplicationFiled: July 30, 2012Publication date: February 28, 2013Applicant: Erimos Pharmaceuticals LLCInventors: Qingqi Chen, Jonathan Daniel Heller, Rocio Alejandra Lopez, Amanda Jean Morris
-
Patent number: 8232277Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.Type: GrantFiled: October 2, 2007Date of Patent: July 31, 2012Assignee: Erimos Pharmaceuticals LLCInventors: Qingqi Chen, Jonathan Daniel Heller, Rocio Alejandra Lopez, Amanda Jean Morris
-
Patent number: 8178527Abstract: Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.Type: GrantFiled: October 2, 2007Date of Patent: May 15, 2012Assignee: Erimos Pharmaceuticals LLCInventors: Qingqi Chen, Rocio Alejandra Lopez, Jonathan Daniel Heller, Amanda Jean Morris
-
Publication number: 20120029216Abstract: A manufacturing process for making terameprocol (1) which includes the following reaction scheme, wherein a first general reaction is the formation of a furan intermediate (39) and a second general reaction is the ring-reduction and ring-opening of the furan intermediate (39) to form the terameprocol (1):Type: ApplicationFiled: July 31, 2009Publication date: February 2, 2012Applicant: Erimos Pharmaceuticals LLCInventors: Qingqi Chen, Jessica Andrea Blomburg
-
Patent number: 7728036Abstract: The present invention provides kits, methods and compositions for the treatment of tumor and other proliferative diseases such as tumors. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA compounds in a pharmaceutically acceptable carrier or excipient. The catecholic butane such as NDGA or its derivatives are administered to one or more subjects in need of treatment by a route other than direct injection into the affected tissues or topical application on affected tissues.Type: GrantFiled: November 21, 2005Date of Patent: June 1, 2010Assignees: Erimos Pharmaceuticals, LLC, Johns Hopkins UniversityInventors: Ru Chih C. Huang, Richard Park, Chih-Chuan Chang, Yu-Chuan Liang, David Mold, Elaine Lin, Jonathan Heller, Neil Frazer
-
Publication number: 20100093872Abstract: A novel pharmaceutical formulation and process for manufacturing an aqueous based formulation of drugs with low or no water solubility. The drug is combined with the inclusion carrier cyclodextrin, eliminating the need for using organic solvents, to combine the drug, in an aqueous solution of cyclodextrin and heating the resulting mixture above its melting point and allowing the drug to be drawn into the cyclodextrin.Type: ApplicationFiled: October 13, 2009Publication date: April 15, 2010Applicant: Erimos Pharmaceuticals LLCInventors: Jessica Andrea LoDuca Blomberg, Anthony Stephen Chilton, Thomas Samuel Ingellinera
-
Publication number: 20100022528Abstract: Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.Type: ApplicationFiled: October 2, 2007Publication date: January 28, 2010Applicant: ERIMOS PHARMACEUTICALS LLC.Inventors: Qingqi Chen, Rocio Alejandra Lopez, Jonathan Daniel Heller, Amanda Jean Morris
-
Publication number: 20090306070Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.Type: ApplicationFiled: October 2, 2007Publication date: December 10, 2009Applicant: Erimos Pharmaceuticals LLCInventors: Jonathan Daniel Heller, Qingqi Chen, Rocio Alejandra Lopez, Amanda Jean Morris
-
Publication number: 20090022803Abstract: The present invention provides for compositions, kits and methods for treatment of diseases, where the compositions contain catecholic butanes, including NDGA compounds, such as NDGA derivatives, for example tetra-O-methyl NDGA. The present invention also provides for solubilizing agents and excipients that are suitable for administration of the present compounds into animals via an oral route, whether in a liquid, semi-solid or solid form.Type: ApplicationFiled: January 27, 2006Publication date: January 22, 2009Applicant: ERIMOS PHARMACEUTICALS LLCInventors: Rocio Alejandra Lopez, Jessica Andrea LoDuca Blomberg, Melissa Claire Rhodes, Jonathan Daniel Heller, Amanda Beth Goodman
-
Publication number: 20080096967Abstract: The present invention provides for a composition, kit and method for treatment of diseases, where the composition contains at least one catecholic butane, including NDGA compounds and derivatives, together with a pharmaceutically acceptable carrier that may include solubilizing agents or excipients, where the composition is suitable for injection into animals.Type: ApplicationFiled: January 27, 2006Publication date: April 24, 2008Applicant: ERIMOS PHARMACEUTICALS LLCInventors: Rocio Lopez, Jessica Blomberg, Melissa Rhodes, Jonathan Heller
-
Publication number: 20080004346Abstract: The present invention provides for compositions, kits and methods for treatment of intraepithelial neoplasia, where the compositions include catecholic butanes, which include NDGA derivatives.Type: ApplicationFiled: July 19, 2005Publication date: January 3, 2008Applicants: ERIMOS PHARMACEUTICALS LLC, JOHNS HOPKINS UNIVERSITY, UNIVERSITY OF MARYLAND, BALTIMOREInventors: Neil Frazer, Jonathan Heller, Rocio Lopez, Melissa Rhodes, Ru Chih Huang, Richard Dalby, Niharika Khanna